A5049948035- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Ovarian cancer diagnosis and treatment
- BRCA gene mutations in cancer
- Testicular diseases and treatments
- Brain Metastases and Treatment
- Pleural and Pulmonary Diseases
- Immunotherapy and Immune Responses
- Health Systems, Economic Evaluations, Quality of Life
- Neutropenia and Cancer Infections
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- PARP inhibition in cancer therapy
- Occupational and environmental lung diseases
- Breast Lesions and Carcinomas
- Cytokine Signaling Pathways and Interactions
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
University Hospitals Bristol NHS Foundation Trust
2015-2025
University Hospitals Bristol and Weston NHS Foundation Trust
2021-2025
University of Oxford
2001-2024
National Health Service
2023
At Bristol
2007-2022
NIHR Bristol Cardiovascular Biomedical Research Unit
2018
Memorial Sloan Kettering Cancer Center
2018
Georgetown University
2018
University of Toronto
2018
Institute of Cancer Research
2017-2018
BackgroundCirculating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile advanced cancer, without need to repeat biopsy. We aimed assess accuracy ctDNA in breast cancer and ability select patients for mutation-directed therapy.MethodsWe did an open-label, multicohort, phase 2a, platform trial 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed Eastern Cooperative Oncology Group performance status 0–2. Patients had...
BackgroundThe optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double targeting approach steroidal anti-oestrogen fulvestrant in combination continued oestrogen deprivation.MethodsIn composite, multicentre, phase 3 randomised controlled done UK and South Korea, (oestrogen receptor [ER] positive, progesterone...
Abstract Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed standardized scoring guidelines have been widely embraced by the research communities. We evaluated sources of variability sTIL assessment pathologists three previous ring studies. identify common challenges evaluate impact...
PURPOSE: N-Benzoyl staurosporine (PKC412) is a protein kinase C inhibitor with antitumor activity in laboratory models. We determined the toxicity of oral PKC412 administered daily for repeat cycles 28 days. PATIENTS AND METHODS: Thirty-two patients advanced solid cancers were treated at seven dose levels (12.5 to 300 mg daily) total 68 cycles. RESULTS: The most frequent treatment-related toxicities nausea, vomiting, fatigue, and diarrhea. At two top (225 mg/d), 15 16 experienced...
Tumor necrosis factor (TNF) alpha is a key player in the tumor microenvironment and involved pathogenesis of breast cancer. Etanercept recombinant human soluble p75 TNF receptor that binds to TNF-alpha renders it biologically unavailable. In current study, we sought determine toxicity, biological activity, therapeutic efficacy metastatic cancer.We initiated Phase II, nonrandomized, open-labeled study patients with progressive cancer refractory conventional therapy (Phase I toxicity data were...
Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation vital. The Trial Imaging and Surveillance Seminoma Testis (TRISST) assessed whether magnetic resonance images (MRIs) or a reduced scan schedule could be used without unacceptable increase advanced relapses.A phase III, noninferiority, factorial trial. Eligible participants had undergone orchiectomy...
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer
Convincing data support the link between inflammation and ovarian cancer. Tumor necrosis factor-alpha (TNF-alpha), a major mediator of inflammation, is chronically produced in tumor microenvironment may enhance growth invasion by inducing secretion cytokines, proangiogenic factors, metalloproteinases. Etanercept recombinant human soluble p75 TNF receptor that binds to TNF-alpha renders it biologically unavailable. In current study, we sought determine toxicity, biologic activity, therapeutic...
503 Background: Suppressing ovarian function of women with breast cancer may improve outcome by preventing estrogenic stimulation any residual cancer, particularly for pre-menopausal estrogen receptor (ER)-positive tumors. We report a collaborative meta-analysis individual participant data from randomized trials ablation or suppression. Methods: Data were sought that compared suppression versus not. Primary analyses included only premenopausal age < 55 ER-positive unknown tumors,...
MetXia-P450 is a novel recombinant retroviral vector that encodes the human cytochrome P450 type 2B6 gene (CYP2B6), Escherichia coli lacZ, and neomycin resistance marker genes. Cytochrome enzymes are primarily expressed in liver convert prodrug cyclophosphamide to an active phosphoramide mustard acrolein. Gene-based delivery of CYP2B6 tumor site leads local activation higher concentrations metabolites at target site.MetXia-P450 was directly injected into metastatic cutaneous nodules on days...
Brain metastases (BM) are a significant complication of metastatic breast cancer (MBC). The high incidence BM in HER2 overexpressing MBC is now well recognized, however, the optimal management such patients not yet clearly defined. We aimed to analyze factors affecting survival after diagnosis treated our center.Retrospective analysis all with antineoplastic therapy for from institution between May 1st 2002 and April 30th 2005, according expression use trastuzumab BM.The median 26 disease...
Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care. Consecutive patients with MPM who were considered fit for first-line chemotherapy prospectively recruited. Patients of similar performance status opting best supportive care included as a comparator group. Baseline interval CT, PET-CT serum (mesothelin, fibulin-3 neutrophil–lymphocyte ratio (NLR)) obtained, followed up minimum 12 months. Seventy-three...
Bloom's syndrome (BS) is a genetic disorder associated with short stature, fertility defects, and predisposition to the development of cancer. BS cells are characterized by genomic instability; in particular, high rate reciprocal exchanges between sister-chromatids homologous chromosomes. The gene product, BLM, helicase belonging highly conserved RecQ family. BLM known form complex RAD51 recombinase, act upon DNA intermediates that during recombination, including D-loops Holliday junctions....